Profibrotic pathway (collective term for fibrosis-promoting signaling cascades)

Profibrotic pathways include a set of interconnected cellular signaling networks that drive excessive deposition of extracellular matrix and tissue scarring in response to chronic injury or dysregulated repair. Central mediators include transforming growth factor-beta (TGF-β), PDGF, FGF, connective tissue growth factor (CTGF), and cytokines such as IL-6 and IL-11[2][7]. Key signaling cascades are SMAD-dependent and independent TGF-β pathways, JAK/STAT, MAPK, PI3K/AKT, and WNT/β-catenin. These pathways regulate the activation and differentiation of fibroblasts into myofibroblasts, promote cell proliferation, apoptosis, and alter immune responses, contributing to fibrosis in organs such as lungs, liver, heart, and kidney[2][5][7][8]. Profibrotic pathways are not a single molecular entity but a group of therapeutic targets for anti-fibrotic drug development. A more specific molecular target name (such as “Transforming growth factor beta 1 receptor,” “STAT3,” or “Interleukin-11 receptor alpha”) should be selected for structured databases and drug development purposes.

Other names

Profibrotic signaling pathwaysfibrosis-promoting signalingfibrotic cascades

Inhibition of TGFβ signaling (blocks activation of SMADs and downstream gene transcription). Kinase inhibition (e.g., JAK, MAPK, c-ABL inhibition). Blockade of specific profibrotic cytokines and receptors (e.g., IL-6, IL-11, CCR2). Epigenetic modulation (e.g., HDAC inhibition, modifies fibroblast activation).